Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Genzyme collaboration ‘to make major positive difference’

Genzyme collaboration ‘to make major positive difference’

28th July 2008

Genzyme’s global collaboration to develop PTC’s oral therapy for nonsense mutation-based genetic disorders is intended to make "a major positive difference" in the lives of patients, according to the firm.

Commenting on plans to develop and commercialise PTC124, Genzyme chairman and chief executive officer Henri A Termeer noted that Genzyme has previously developed four therapies for patients with severe genetic diseases.

"PTC124 is a powerful new approach that holds great potential to help CF [cystic fibrosis] and DMD [Duchenne muscular dystrophy] patients and many others with a variety of devastating diseases," he observed.

Mr Termeer’s colleague, Dr Geoff McDonough, added that PTC124 illustrates the potential of personalised medicine "to address significant unmet medical needs" and expressed his firm’s aim to "make a major positive difference" to the lives of patients and their families.

As part of the agreement, biotechnology specialist PTC will commercialise PTC124 in the US and Canada, while Genzyme will commercialise the treatment in other countries.

In addition to DMD and CF, the companies plan to explore PTC124’s potential to benefit patients with other severe and debilitating genetic diseases.ADNFCR-1050-ID-18703867-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.